- ProductsInvestment SuiteExclusiveFeatures
- PlatformTrading PlatformsFeatures and ToolsCalculatorsPricing
- ResearchResearch CallsResearch Reports
- MarketMarket MoversStocksIndicesMutual FundsIPO
- LearnStockshaalaResourceInvesting GuideEvents
- Partner
- Support
Products
Platform
Research
Market
Learn
Compare Nippon India Pharma Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | 3.0 | 4.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 1.8 | 1.89 |
NAV | ₹513.89 | ₹39.37 |
Fund Started | 10 May 2004 | 25 Jun 2018 |
Fund Size | ₹8352.16 Cr | ₹5507.52 Cr |
Exit Load | Exit load of 1% if redeemed within 1 month. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
3.0
4.0
Min SIP Amount
₹100
₹100
Expense Ratio
1.8
1.89
NAV
₹513.89
₹39.37
Fund Started
10 May 2004
25 Jun 2018
Fund Size
₹8352.16 Cr
₹5507.52 Cr
Exit Load
Exit load of 1% if redeemed within 1 month.
Exit load of 1% if redeemed within 15 days.
Returns
1 Year | 13.72% | 21.93% |
3 Year | 25.49% | 29.75% |
5 Year | 21.99% | 25.03% |
1 Year
13.72%
21.93%
3 Year
25.49%
29.75%
5 Year
21.99%
25.03%
Holding Analysis
Equity | 98.60% | 96.99% |
Cash | 1.40% | 3.01% |
Equity
98.60%
96.99%
Cash
1.40%
3.01%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 12.57% |
Divi's Laboratories Ltd. | 9.49% |
Lupin Ltd. | 5.82% |
Cipla Ltd. | 5.62% |
Dr. Reddy's Laboratories Ltd. | 5.49% |
Apollo Hospitals Enterprise Ltd. | 5.34% |
Medplus Health Services Ltd. | 4.20% |
Glaxosmithkline Pharmaceuticals Ltd. | 3.73% |
Vijaya Diagnostic Centre Ltd. | 3.24% |
Narayana Hrudayalaya Ltd. | 2.94% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 12.66% |
Dr. Reddy's Laboratories Ltd. | 9.66% |
Divi's Laboratories Ltd. | 9.03% |
Cipla Ltd. | 7.85% |
Aurobindo Pharma Ltd. | 6.34% |
Alkem Laboratories Ltd. | 4.12% |
Zydus Lifesciences Ltd. | 4.01% |
Lupin Ltd. | 3.98% |
Gland Pharma Ltd. | 3.95% |
Syngene International Ltd. | 2.46% |
Fund Manager
Name | Akshay Sharma | Dharmesh Kakkad |
Start Date | 01 Dec 2022 | 23 Feb 2021 |
Name
Akshay Sharma
Dharmesh Kakkad
Start Date
01 Dec 2022
23 Feb 2021
About Fund
Description | The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 10 May 2004 | 25 Jun 2018 |
Description
The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
10 May 2004
25 Jun 2018